Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Oncotelic Therapeutics, Inc.exh_991.htm
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 13, 2011

OXiGENE, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
0-21990
13-3679168
(State or other
(Commission File
(I.R.S. Employer
jurisdiction of
Number)
Identification No.)
incorporation)
   
 
701 Gateway Boulevard, Suite 210, South San Francisco, CA 94080
(Address of principal executive offices)

Registrant's telephone number, including area code: (650) 635-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[_]  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
Item 7.01  Regulation FD Disclosure.
 
On October 13, 2011 the Registrant posted a letter on the Registrant’s corporate web site, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
 
Item 9.01. Financial Statements and Exhibits.
 
Exhibit 99.1.    Letter dated October 13, 2011.
 
 
 
 

 
 
SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  OXiGENE, Inc.
   
Date: October 14, 2011
/s/ PETER J. LANGECKER
 
By: Peter J. Langecker
 
Chief Executive Officer
 
 

 
 

 
 

 
Exhibit Index
 
99.1
Letter dated October 13, 2011